Blauvelt, A., P. Rich, H. Sofen, J. Lambert, J. F. Merola, M. Lebwohl, T. Scharnitz, K. Hoyt, R. M. Kisa, and S. Banerjee. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis: Subgroup Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s49, doi:10.25251/skin.6.supp.49.